Novel use of peptide compounds for treating pain in painful diabetic neuropathy

Details for Australian Patent Application No. 2005226928 (hide)

Owner Schwarz Pharma AG

Inventors Koch, Brigitte; Rauschkolb-Loffler, Christine

Agent Davies Collison Cave

Pub. Number AU-B-2005226928

PCT Pub. Number WO2005/092313

Priority 04007360.3 26.03.04 EP; 60/556,499 26.03.04 US

Filing date 24 March 2005

Wipo publication date 6 October 2005

Acceptance publication date 13 May 2010

International Classifications

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

Event Publications

28 September 2006 PCT application entered the National Phase

  PCT publication WO2005/092313 Priority application(s): WO2005/092313

13 May 2010 Application Accepted

  Published as AU-B-2005226928

9 September 2010 Standard Patent Sealed

16 December 2010 Alteration of Name

  The name of the patentee has been altered to UCB Pharma GmbH

18 October 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005226932-Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen

2005226927-Gastroresistant pharmaceutical dosage form comprising N- (2-(2-phthalimidoethoxy)-acetyl)-L-alan yl-D-glutamic acid (LK-423)